Moderna (MRNA) Revenue — Quarter Ended Sep 30, 2024
Revenue for the quarter increased sharply compared to the immediately preceding quarter. The reported revenue also rose slightly versus the same quarter one year earlier.
Key takeaway
Quarter ended Sep 30, 2024 · FY2024 Q3
Revenue for the quarter increased sharply compared to the immediately preceding quarter. The reported revenue also rose slightly versus the same quarter one year earlier.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$1.9B
Revenue reported for this quarter.
Quarter-over-quarter
+672.6%
Change from the immediately preceding quarter.
Year-over-year
+1.7%
Change from the comparable year-ago quarter.
Trailing four quarters
$5.1B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2023 | $2.8B | -44.7% |
| Mar 31, 2024 | $167M | -91.0% |
| Jun 30, 2024 | $241M | -29.9% |
| Sep 30, 2024 | $1.9B | +1.7% |
Revenue performance
The reported revenue direction is upward, reflecting a substantial sequential gain from the prior quarter. On a year-over-year basis, revenue showed a modest increase.
Quarterly comparison
Compared with the immediately preceding quarter, revenue experienced a very large percentage increase. Relative to the same quarter one year earlier, revenue was slightly higher.
What to watch
The filing context does not provide specific commentary on revenue drivers for this quarter.